Catabasis Pharmaceuticals, Inc. (“Catabasis,” the “Company,” “we,” “our,” or “us”) (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it intends to offer its securities in an underwritten public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Oppenheimer & Co. Inc. is acting as sole underwriter for the offering.
Catabasis intends to use the net proceeds from the offering for clinical trial and other research and development activities; continued growth of its manufacturing capabilities; initial investments in commercial and medical affairs infrastructure to support its transition to a commercial-stage company; and for working capital and other general corporate purposes.
The securities described above will be offered pursuant to a shelf registration statement on Form S-3 (No. 333-212382) that was previously filed with and declared effective by the Securities and Exchange Commission (“SEC”) on July 19, 2016. A preliminary prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov, copies of which may be obtained, when available, from Oppenheimer & Co. Inc. Attention: Syndicate Prospectus Department, 85 Broad St., 26th Floor, New York, NY 10004, by telephone at (212) 667-8055 or by email at EquityProspectus@opco.com. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Catabasis
At Catabasis Pharmaceuticals, our mission is
to bring hope and life-changing therapies to patients and their
families. Our lead program is edasalonexent, an NF-kB inhibitor in
development for the treatment of Duchenne muscular dystrophy. Our global
Phase 3 PolarisDMD trial is currently enrolling boys affected by
Duchenne. For more information on edasalonexent and our Phase 3
PolarisDMD trial, please visit www.catabasis.com
or www.twitter.com/catabasispharma.
Forward Looking Statements
Any statements in this press
release about future expectations, plans and prospects for the Company,
including statements about the anticipated completion, timing and size
of the public offering and the anticipated use of net proceeds
therefrom, among other things, statements containing the words
“believes,” “anticipates,” “plans,” “expects,” “may” and similar
expressions, constitute forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. The offering is
subject to market and other conditions and there can be no assurance as
to whether or when the offering may be completed or as to the actual
size or terms of the offering. Actual results may differ materially from
those indicated by such forward-looking statements as a result of
various important factors, including: market conditions that may affect
the timing, terms and conditions of the offering, our ability to satisfy
the conditions to closing of the offering and other matters affecting
our ability to consummate the offering on terms acceptable to us. In
addition, the forward-looking statements included in this press release
represent the Company’s views as of the date of this press release. The
Company anticipates that subsequent events and developments will cause
the Company’s views to change. However, while the Company may elect to
update these forward-looking statements at some point in the future, the
Company specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as representing the
Company’s views as of any date subsequent to the date of this release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190205005955/en/
Contacts:
Andrea
Matthews
Catabasis Pharmaceuticals, Inc.
(617) 349-1971
amatthews@catabasis.com